Next Article in Journal
Identifying Knowledge Gaps among LVAD Candidates
Previous Article in Journal
The Role of Laparoscopic Investigation in Enabling Natural Conception and Avoiding in vitro Fertilization Overuse for Infertile Patients of Unidentified Aetiology and Recurrent Implantation Failure Following in vitro Fertilization
Article Menu
Issue 4 (April) cover image

Export Article

J. Clin. Med. 2019, 8(4), 546; https://doi.org/10.3390/jcm8040546

Correction
Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538
1
School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824, Taiwan
2
Division of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan
3
Department of Critical Care Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan
4
Department of Biological Science and Technology, Meiho University, Pingtung 912, Taiwan
*
Author to whom correspondence should be addressed.
Received: 19 April 2019 / Accepted: 22 April 2019 / Published: 22 April 2019
The authors wish to make the following corrections to this paper [1].
The authors have made a critical typing error and a counting error in Table 2 as the parameters of “Community-acquired infection” and “Healthcare-associated infection” were mistakenly switched with each other.
Accordingly, Table 2, which is shown as follows:
Table 2. Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
Table 2. Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
CharacteristicsAll (n = 92)Number of Episodes (%)OR (95% CI)p-Value
E. meningoseptica
(n = 20)
E. anophelis
(n = 72)
Sex
Male64 (69.6)15 (75)49 (68.1)1.41 (0.46–4.35)0.55
Female28 (30.4)5 (25)23 (31.9)0.71 (0.23–2.19)0.55
Age
Range (year)3–8918–803–89
Median (year)616162.5
Mean ± standard deviation (year)61.1 ± 1756.6 ± 15.662.4 ± 17.3 0.179
Comorbidity
Diabetes mellitus24 (26.1)6 (30)18 (25)1.29 (0.43–3.84)0.652
Hypertension26 (28.3)4 (20)22 (30.6)0.57 (0.17–1.9)0.354
End-stage renal disease5 (5.4)1 (5)4 (5.6)0.9 (0.09–8.49)0.999
Malignancy40 (43.5)8 (40)32 (44.4)0.83 (0.3-2.28)0.723
Liver cirrhosis8 (8.7)3 (15)5 (6.9)2.37 (0.51–10.89)0.365
Chronic obstructive pulmonary disease 9 (9.8)09 (12.5) 0.197
Type of infection acquisition
Community-acquired infection10 (10.9)2063 (87.5) 0.197
Healthcare-associated infection82 (89.1)09 (12.5) 0.197
Laboratory data
White blood cell count (cells/mm3)13,281 ± 874013,353 ± 668713,261 ± 9271 0.967
Hemoglobin (g/dL)10.1 ± 2.19.8 ± 2.410.1 ± 2.1 0.585
Platelet count (×1000 cells/mm3)228,570 ± 131,056216,550 ± 157,332231,900 ± 123,846 0.69
Serum creatinine (mg/dL)1.8 ± 1.71.6 ± 1.31.9 ± 1.8 0.584
Empirical antimicrobial therapy
β-lactams41 (44.6)11 (55)30 (41.7)1.71 (0.63–4.64)0.289
β-lactam/lactamase inhibitors20 (21.7)4 (20)16 (22.2)0.88 (0.26–2.99)0.999
Ciprofloxacin10 (10.9)1 (5)9 (12.5)0.37 (0.04–3.1)0.685
Levofloxacin24 (26.1)1 (5)23 (31.9)0.11 (0.01–0.89)0.015
Carbapenems17 (18.5)4 (20)13 (18.1)1.14 (0.33–3.96)0.999
Aminoglycosides9 (9.8)3 (15)6 (8.3)1.94 (0.44–8.57)0.402
Tigecycline8 (8.7)2 (10)6 (8.3)1.22 (0.23–6.58)0.999
Colistin6 (6.5)1 (5)5 (6.9)0.71 (0.08–6.41)0.999
Inappropriate empirical antimicrobial therapy74 (80.4)20 (100)54 (75) 0.01
Shock42 (45.7)9 (45)33 (45.8)0.97 (0.36–2.62)0.999
Admission to intensive care unit44 (47.8)9 (45)35 (48.6)0.87 (0.32–2.34)0.775
Case fatality25 (27.2)6 (30)19 (26.4)1.2 (0.4–3.56)0.748
Abbreviations: OR, odds ratio; CI, confidence interval.
should be replaced with the following:
Table 2. Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
Table 2. Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
CharacteristicsAll (n = 92)Number of Episodes (%)OR (95% CI)p-Value
E. meningoseptica
(n = 20)
E. anophelis
(n = 72)
Sex
Male64 (69.6)15 (75)49 (68.1)1.41 (0.46–4.35)0.55
Female28 (30.4)5 (25)23 (31.9)0.71 (0.23–2.19)0.55
Age
Range (year)3–8918–803–89
Median (year)616162.5
Mean ± standard deviation (year)61.1 ± 1756.6 ± 15.662.4 ± 17.3 0.179
Comorbidity
Diabetes mellitus24 (26.1)6 (30)18 (25)1.29 (0.43–3.84)0.652
Hypertension26 (28.3)4 (20)22 (30.6)0.57 (0.17–1.9)0.354
End-stage renal disease5 (5.4)1 (5)4 (5.6)0.9 (0.09–8.49)0.999
Malignancy40 (43.5)8 (40)32 (44.4)0.83 (0.3-2.28)0.723
Liver cirrhosis8 (8.7)3 (15)5 (6.9)2.37 (0.51–10.89)0.365
Chronic obstructive pulmonary disease 9 (9.8)09 (12.5) 0.197
Type of infection acquisition
Community-acquired infection9 (9.8)09 (12.5) 0.197
Healthcare-associated infection83 (90.2)2063 (87.5) 0.197
Laboratory data
White blood cell count (cells/mm3)13,281 ± 874013,353 ± 668713,261 ± 9271 0.967
Hemoglobin (g/dL)10.1 ± 2.19.8 ± 2.410.1 ± 2.1 0.585
Platelet count (×1000 cells/mm3)228,570 ± 131,056216,550 ± 157,332231,900 ± 123,846 0.69
Serum creatinine (mg/dL)1.8 ± 1.71.6 ± 1.31.9 ± 1.8 0.584
Empirical antimicrobial therapy
β-lactams41 (44.6)11 (55)30 (41.7)1.71 (0.63–4.64)0.289
β-lactam/lactamase inhibitors20 (21.7)4 (20)16 (22.2)0.88 (0.26–2.99)0.999
Ciprofloxacin10 (10.9)1 (5)9 (12.5)0.37 (0.04–3.1)0.685
Levofloxacin24 (26.1)1 (5)23 (31.9)0.11 (0.01–0.89)0.015
Carbapenems17 (18.5)4 (20)13 (18.1)1.14 (0.33–3.96)0.999
Aminoglycosides9 (9.8)3 (15)6 (8.3)1.94 (0.44–8.57)0.402
Tigecycline8 (8.7)2 (10)6 (8.3)1.22 (0.23–6.58)0.999
Colistin6 (6.5)1 (5)5 (6.9)0.71 (0.08–6.41)0.999
Inappropriate empirical antimicrobial therapy74 (80.4)20 (100)54 (75) 0.01
Shock42 (45.7)9 (45)33 (45.8)0.97 (0.36–2.62)0.999
Admission to intensive care unit44 (47.8)9 (45)35 (48.6)0.87 (0.32–2.34)0.775
Case fatality25 (27.2)6 (30)19 (26.4)1.2 (0.4–3.56)0.748
Abbreviations: OR, odds ratio; CI, confidence interval.
The authors apologize for any inconvenience caused to the readers by these changes.

Reference

  1. Lin, J.-N.; Lai, C.-H.; Yang, C.-H.; Huang, Y.-H. Comparison of clinical manifestations, antimicrobial susceptibility patterns, and mutations of fluoroquinolone target genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis isolated in Taiwan. J. Clin. Med. 2018, 7, 538. [Google Scholar] [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top